Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Id-1 mediates glioma stem cell survival in response to chemotherapy
FY 2014-15
Summary
Glioblastoma (GBM) is the most common malignant primary brain tumour in adults, accounting for over 50% of all types of primary central nervous system gliomas. This malignancy is associated with an aggressive clinical course and poor prognosis, with a median overall survival of less than 15 months. This poor prognosis is despite maximal treatment, which typically consists of a combination of radiotherapy and chemotherapy.Resistance to chemotherapeutic drugs is one of the major reasons for treatment failure in glioblastoma.This has prompted researchers to investigate mechanisms of chemoresistance within glioblastoma, which has opened new exciting areas of research.
One protein of interest that has been studied with respect to chemoresistance in various cancer cells is Id-1 (inhibitor of differentiation and DNA binding). It has been suggestedthat high expression of Id-1 may provide an advantage for cancer cell survival, allowing the cancer cells to escape cell death when treated with chemotherapy. It is believed that these chemoresistant cancer cells are responsible for driving tumour recurrence, and patients will ultimatelysuccumb to the recurrent disease. Therefore, by inactivating Id-1 wemay be able to increase the cancer cells' susceptibility to cell death, and inhibit tumour recurrence. The proposed studyis aimed at elucidating the role of Id-1 in glioblastoma chemoresistance. The significance of the proposed study to health science is Id-1 inactivation may be able to induce sensitivity of glioma stem cells to chemotherapeutic drugs, providing a novel and promising strategy for improving the therapy and outcome of patients with glioblastoma.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331366
Name
Celebre Angela M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Id-1 mediates glioma stem cell survival in response to chemotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Stem Cells; Chemoresistance Mechanism; Glioblastoma; Inhibitor Of Differentiation And Dna Binding 1 (Id-1); Survival Outcome; Temozolomide
Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumour in adults, accounting for over 50% of all types of primary central nervous system gliomas. This malignancy is associated with an aggressive clinical course and poor prognosis, with a median overall survival of less than 15 months. This poor prognosis is despite maximal treatment, which typically consists of a combination of radiotherapy and chemotherapy.Resistance to chemotherapeutic drugs is one of the major reasons for treatment failure in glioblastoma.This has prompted researchers to investigate mechanisms of chemoresistance within glioblastoma, which has opened new exciting areas of research.
One protein of interest that has been studied with respect to chemoresistance in various cancer cells is Id-1 (inhibitor of differentiation and DNA binding). It has been suggestedthat high expression of Id-1 may provide an advantage for cancer cell survival, allowing the cancer cells to escape cell death when treated with chemotherapy. It is believed that these chemoresistant cancer cells are responsible for driving tumour recurrence, and patients will ultimatelysuccumb to the recurrent disease. Therefore, by inactivating Id-1 wemay be able to increase the cancer cells' susceptibility to cell death, and inhibit tumour recurrence. The proposed studyis aimed at elucidating the role of Id-1 in glioblastoma chemoresistance. The significance of the proposed study to health science is Id-1 inactivation may be able to induce sensitivity of glioma stem cells to chemotherapeutic drugs, providing a novel and promising strategy for improving the therapy and outcome of patients with glioblastoma.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Celebre, Angela M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~